The NK-AML mutational landscape was characterized by a diversity in implicated TCGA functional groups, including activated signaling (41%), transcription factors (19%), NPM1 (14%), tumor suppressors/WT1 (10%), and DNA methylation (7%). The gene discussed is WT1; the disease is acute myeloid leukemia.